FLOT versus FLOT/Trastuzumab/Pertuzumab perioperative therapy of human epidermal growth factor receptor 2-positive resectable esophagogastric adenocarcinoma: a randomized phase II trial of the AIO EGA study group
High pathologic complete response (pCR) rates and comparably good survival data were seen in a phase II trial combining perioperative fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) chemotherapy with trastuzumab for resectable, esophagogastric adenocarcinoma (EGA). The current trial eval...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
June 16, 2022
|
| In: |
Journal of clinical oncology
Year: 2022, Jahrgang: 40, Heft: 32, Pages: 3750-3761 |
| ISSN: | 1527-7755 |
| DOI: | 10.1200/JCO.22.00380 |
| Online-Zugang: | Resolving-System, Volltext: https://doi.org/10.1200/JCO.22.00380 Verlag, Volltext: https://ascopubs.org/doi/10.1200/JCO.22.00380 
|
| Verfasserangaben: | Ralf-Dieter Hofheinz, Kirsten Merx, Georg M. Haag, Christoph Springfeld, Thomas Ettrich, Kersten Borchert, Albrecht Kretzschmar, Christian Teschendorf, Gabriele Siegler, Matthias P. Ebert, Eray Goekkurt, Rolf Mahlberg, Nils Homann, Daniel Pink, Wolf Bechstein, Peter Reichardt, Hagen Flach, Timo Gaiser, Achim Battmann, Fuat S. Oduncu, Maria Loose, Disorn Sookthai, Claudia Pauligk, Thorsten O. Göetze, and Salah-Eddin Al-Batran |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1832198502 | ||
| 003 | DE-627 | ||
| 005 | 20241205100519.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230125s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1200/JCO.22.00380 |2 doi | |
| 035 | |a (DE-627)1832198502 | ||
| 035 | |a (DE-599)KXP1832198502 | ||
| 035 | |a (OCoLC)1389535789 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Hofheinz, Ralf-Dieter |d 1969- |e VerfasserIn |0 (DE-588)121917517 |0 (DE-627)08161876X |0 (DE-576)292991568 |4 aut | |
| 245 | 1 | 0 | |a FLOT versus FLOT/Trastuzumab/Pertuzumab perioperative therapy of human epidermal growth factor receptor 2-positive resectable esophagogastric adenocarcinoma |b a randomized phase II trial of the AIO EGA study group |c Ralf-Dieter Hofheinz, Kirsten Merx, Georg M. Haag, Christoph Springfeld, Thomas Ettrich, Kersten Borchert, Albrecht Kretzschmar, Christian Teschendorf, Gabriele Siegler, Matthias P. Ebert, Eray Goekkurt, Rolf Mahlberg, Nils Homann, Daniel Pink, Wolf Bechstein, Peter Reichardt, Hagen Flach, Timo Gaiser, Achim Battmann, Fuat S. Oduncu, Maria Loose, Disorn Sookthai, Claudia Pauligk, Thorsten O. Göetze, and Salah-Eddin Al-Batran |
| 246 | 3 | 0 | |a FLOT Trastuzumab Pertuzumab / |
| 264 | 1 | |c June 16, 2022 | |
| 300 | |a 12 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 25.01.2023 | ||
| 520 | |a High pathologic complete response (pCR) rates and comparably good survival data were seen in a phase II trial combining perioperative fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) chemotherapy with trastuzumab for resectable, esophagogastric adenocarcinoma (EGA). The current trial evaluates the addition of trastuzumab and pertuzumab to FLOT as perioperative treatment for human epidermal growth factor receptor 2-positive resectable EGA. | ||
| 700 | 1 | |a Merx, Kirsten |d 1970- |e VerfasserIn |0 (DE-588)122413091 |0 (DE-627)70589892X |0 (DE-576)293258910 |4 aut | |
| 700 | 1 | |a Haag, Georg Martin |d 1979- |e VerfasserIn |0 (DE-588)133390934 |0 (DE-627)544043863 |0 (DE-576)29981548X |4 aut | |
| 700 | 1 | |a Springfeld, Christoph |d 1972- |e VerfasserIn |0 (DE-588)123388910 |0 (DE-627)706281039 |0 (DE-576)293689385 |4 aut | |
| 700 | 1 | |a Ettrich, Thomas |e VerfasserIn |4 aut | |
| 700 | 1 | |a Borchert, Kersten |e VerfasserIn |4 aut | |
| 700 | 1 | |a Kretzschmar, Albrecht |e VerfasserIn |4 aut | |
| 700 | 1 | |a Teschendorf, Christian |e VerfasserIn |4 aut | |
| 700 | 1 | |a Siegler, Gabriele |e VerfasserIn |4 aut | |
| 700 | 1 | |a Ebert, Matthias |d 1968- |e VerfasserIn |0 (DE-588)1030133522 |0 (DE-627)734827083 |0 (DE-576)377938432 |4 aut | |
| 700 | 1 | |a Goekkurt, Eray |e VerfasserIn |4 aut | |
| 700 | 1 | |a Mahlberg, Rolf |e VerfasserIn |4 aut | |
| 700 | 1 | |a Homann, Nils |e VerfasserIn |0 (DE-588)1350417475 |0 (DE-627)1910928887 |4 aut | |
| 700 | 1 | |a Pink, Daniel |d 1973- |e VerfasserIn |0 (DE-588)122616952 |0 (DE-627)082050309 |0 (DE-576)293349975 |4 aut | |
| 700 | 1 | |a Bechstein, Wolf |e VerfasserIn |4 aut | |
| 700 | 1 | |a Reichardt, Peter |e VerfasserIn |4 aut | |
| 700 | 1 | |a Flach, Hagen |e VerfasserIn |4 aut | |
| 700 | 1 | |a Gaiser, Timo |d 1975- |e VerfasserIn |0 (DE-588)1030402280 |0 (DE-627)735221685 |0 (DE-576)378226533 |4 aut | |
| 700 | 1 | |a Battmann, Achim |e VerfasserIn |4 aut | |
| 700 | 1 | |a Oduncu, Fuat S. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Loose, Maria |e VerfasserIn |4 aut | |
| 700 | 1 | |a Sookthai, Disorn |e VerfasserIn |4 aut | |
| 700 | 1 | |a Pauligk, Claudia |e VerfasserIn |4 aut | |
| 700 | 1 | |a Göetze, Thorsten O. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Al-Batran, Salah-Eddin |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of clinical oncology |d Alexandria, Va. : American Society of Clinical Oncology, 1983 |g 40(2022), 32, Seite 3750-3761 |h Online-Ressource |w (DE-627)313116962 |w (DE-600)2005181-5 |w (DE-576)090887018 |x 1527-7755 |7 nnas |a FLOT versus FLOT/Trastuzumab/Pertuzumab perioperative therapy of human epidermal growth factor receptor 2-positive resectable esophagogastric adenocarcinoma a randomized phase II trial of the AIO EGA study group |
| 773 | 1 | 8 | |g volume:40 |g year:2022 |g number:32 |g pages:3750-3761 |g extent:12 |a FLOT versus FLOT/Trastuzumab/Pertuzumab perioperative therapy of human epidermal growth factor receptor 2-positive resectable esophagogastric adenocarcinoma a randomized phase II trial of the AIO EGA study group |
| 856 | 4 | 0 | |u https://doi.org/10.1200/JCO.22.00380 |x Resolving-System |x Verlag |3 Volltext |
| 856 | 4 | 0 | |u https://ascopubs.org/doi/10.1200/JCO.22.00380 |x Verlag |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20230125 | ||
| 993 | |a Article | ||
| 994 | |a 2022 | ||
| 998 | |g 1030402280 |a Gaiser, Timo |m 1030402280:Gaiser, Timo |d 60000 |d 63400 |e 60000PG1030402280 |e 63400PG1030402280 |k 0/60000/ |k 1/60000/63400/ |p 18 | ||
| 998 | |g 1030133522 |a Ebert, Matthias |m 1030133522:Ebert, Matthias |d 60000 |d 61100 |e 60000PE1030133522 |e 61100PE1030133522 |k 0/60000/ |k 1/60000/61100/ |p 10 | ||
| 998 | |g 122413091 |a Merx, Kirsten |m 122413091:Merx, Kirsten |d 60000 |d 61200 |e 60000PM122413091 |e 61200PM122413091 |k 0/60000/ |k 1/60000/61200/ |p 2 | ||
| 998 | |g 121917517 |a Hofheinz, Ralf-Dieter |m 121917517:Hofheinz, Ralf-Dieter |d 60000 |d 61200 |e 60000PH121917517 |e 61200PH121917517 |k 0/60000/ |k 1/60000/61200/ |p 1 |x j | ||
| 998 | |g 123388910 |a Springfeld, Christoph |m 123388910:Springfeld, Christoph |d 910000 |d 910100 |d 50000 |e 910000PS123388910 |e 910100PS123388910 |e 50000PS123388910 |k 0/910000/ |k 1/910000/910100/ |k 0/50000/ |p 4 | ||
| 998 | |g 133390934 |a Haag, Georg Martin |m 133390934:Haag, Georg Martin |d 910000 |d 910100 |d 50000 |e 910000PH133390934 |e 910100PH133390934 |e 50000PH133390934 |k 0/910000/ |k 1/910000/910100/ |k 0/50000/ |p 3 | ||
| 999 | |a KXP-PPN1832198502 |e 425128397X | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"title":[{"title_sort":"FLOT versus FLOT/Trastuzumab/Pertuzumab perioperative therapy of human epidermal growth factor receptor 2-positive resectable esophagogastric adenocarcinoma","subtitle":"a randomized phase II trial of the AIO EGA study group","title":"FLOT versus FLOT/Trastuzumab/Pertuzumab perioperative therapy of human epidermal growth factor receptor 2-positive resectable esophagogastric adenocarcinoma"}],"language":["eng"],"type":{"media":"Online-Ressource","bibl":"article-journal"},"origin":[{"dateIssuedKey":"2022","dateIssuedDisp":"June 16, 2022"}],"recId":"1832198502","physDesc":[{"extent":"12 S."}],"id":{"eki":["1832198502"],"doi":["10.1200/JCO.22.00380"]},"note":["Gesehen am 25.01.2023"],"relHost":[{"pubHistory":["1.1983 -"],"title":[{"title_sort":"Journal of clinical oncology","title":"Journal of clinical oncology","subtitle":"JCO : an American Society of Clinical Oncology journal"}],"part":{"pages":"3750-3761","extent":"12","issue":"32","volume":"40","text":"40(2022), 32, Seite 3750-3761","year":"2022"},"language":["eng"],"physDesc":[{"extent":"Online-Ressource"}],"disp":"FLOT versus FLOT/Trastuzumab/Pertuzumab perioperative therapy of human epidermal growth factor receptor 2-positive resectable esophagogastric adenocarcinoma a randomized phase II trial of the AIO EGA study groupJournal of clinical oncology","id":{"issn":["1527-7755"],"zdb":["2005181-5"],"eki":["313116962"]},"note":["Fortsetzung der Druck-Ausgabe","Gesehen am 22.05.23"],"corporate":[{"role":"isb","display":"American Society of Clinical Oncology"}],"titleAlt":[{"title":"official journal of the American Society of Clinical Oncology"},{"title":"JCO"},{"title":"Journal of clinical oncology legacy archive (ASCO)"}],"type":{"media":"Online-Ressource","bibl":"periodical"},"recId":"313116962","origin":[{"dateIssuedKey":"1983","publisher":"American Society of Clinical Oncology ; Lippincott Williams & Wilkins","dateIssuedDisp":"1983-","publisherPlace":"Alexandria, Va. ; Baltimore, Md. [u.a.]"}]}],"name":{"displayForm":["Ralf-Dieter Hofheinz, Kirsten Merx, Georg M. Haag, Christoph Springfeld, Thomas Ettrich, Kersten Borchert, Albrecht Kretzschmar, Christian Teschendorf, Gabriele Siegler, Matthias P. Ebert, Eray Goekkurt, Rolf Mahlberg, Nils Homann, Daniel Pink, Wolf Bechstein, Peter Reichardt, Hagen Flach, Timo Gaiser, Achim Battmann, Fuat S. Oduncu, Maria Loose, Disorn Sookthai, Claudia Pauligk, Thorsten O. Göetze, and Salah-Eddin Al-Batran"]},"person":[{"given":"Ralf-Dieter","role":"aut","display":"Hofheinz, Ralf-Dieter","family":"Hofheinz"},{"family":"Merx","given":"Kirsten","role":"aut","display":"Merx, Kirsten"},{"family":"Haag","given":"Georg Martin","role":"aut","display":"Haag, Georg Martin"},{"family":"Springfeld","display":"Springfeld, Christoph","role":"aut","given":"Christoph"},{"role":"aut","given":"Thomas","display":"Ettrich, Thomas","family":"Ettrich"},{"display":"Borchert, Kersten","role":"aut","given":"Kersten","family":"Borchert"},{"family":"Kretzschmar","given":"Albrecht","role":"aut","display":"Kretzschmar, Albrecht"},{"display":"Teschendorf, Christian","role":"aut","given":"Christian","family":"Teschendorf"},{"display":"Siegler, Gabriele","given":"Gabriele","role":"aut","family":"Siegler"},{"family":"Ebert","given":"Matthias","role":"aut","display":"Ebert, Matthias"},{"family":"Goekkurt","given":"Eray","role":"aut","display":"Goekkurt, Eray"},{"family":"Mahlberg","role":"aut","given":"Rolf","display":"Mahlberg, Rolf"},{"display":"Homann, Nils","role":"aut","given":"Nils","family":"Homann"},{"display":"Pink, Daniel","given":"Daniel","role":"aut","family":"Pink"},{"family":"Bechstein","display":"Bechstein, Wolf","role":"aut","given":"Wolf"},{"family":"Reichardt","given":"Peter","role":"aut","display":"Reichardt, Peter"},{"display":"Flach, Hagen","role":"aut","given":"Hagen","family":"Flach"},{"given":"Timo","role":"aut","display":"Gaiser, Timo","family":"Gaiser"},{"role":"aut","given":"Achim","display":"Battmann, Achim","family":"Battmann"},{"role":"aut","given":"Fuat S.","display":"Oduncu, Fuat S.","family":"Oduncu"},{"family":"Loose","role":"aut","given":"Maria","display":"Loose, Maria"},{"given":"Disorn","role":"aut","display":"Sookthai, Disorn","family":"Sookthai"},{"given":"Claudia","role":"aut","display":"Pauligk, Claudia","family":"Pauligk"},{"role":"aut","given":"Thorsten O.","display":"Göetze, Thorsten O.","family":"Göetze"},{"family":"Al-Batran","display":"Al-Batran, Salah-Eddin","given":"Salah-Eddin","role":"aut"}]} | ||
| SRT | |a HOFHEINZRAFLOTVERSUS1620 | ||